THERAPY DOSSIER · th-148c61c99cad

Exogenous complement C3

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30530169 ↗2018Reported benefit

The mTORC1 signaling modulated by intracellular C3 activation in Paneth cells promotes intestinal epithelial regeneration during acute injury.

MouseOtherC57BL/6 wildtypeIntraperitoneal in vivo; added to culture medium in vitro1 mg in vivo; 20 micrograms/mL in intestinal crypt culture6 h after surgery

Model: Surgically induced acute gastrointestinal injury with sham operation as control; ileal crypt culture used in vitro

Acute gastrointestinal injury broke down mucosal integrity and caused regional inflammation. Exogenous C3 alone did not promote epithelial growth but enhanced Paneth cell activity through intracellular activation, which supported intestinal stem cell expansion within crypts. Blocking C3 activation…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…